Form 4: Rani Therapeutics Director Amends Stock Option Prices
SEC Form 4 Filing
Rani Therapeutics director Lisa Ann Rometty amended the exercise prices of her stock options on December 16, 2024.
Summary
- Lisa Ann Rometty, a director at Rani Therapeutics, modified the exercise prices of her stock options on December 16, 2024.
- The exercise price of 101,276 stock options was increased from $2.84 to $4.11 per share.
- The exercise price of another 17,708 stock options was increased from $2.84 to $17.00 per share.
- There were no changes to the expiration dates or vesting schedules of these options.
- The options vest over time, with some having vested on January 3, 2023, and others vesting monthly over two years.
Sentiment
Score: 5
Explanation: The document is a routine filing regarding stock option adjustments, which is neither positive nor negative in itself. It reflects standard corporate governance practices.
Industry Context
This is a standard SEC Form 4 filing related to changes in beneficial ownership of securities by a company director. It is common for companies to adjust stock option prices, especially in response to market conditions or company performance.
Comparison to Industry Standards
- Stock option grants and amendments are a common practice in publicly traded companies, particularly in the biotech sector where Rani Therapeutics operates.
- The specific terms of the options, such as vesting schedules and exercise prices, are typically determined by the company's compensation policies and market conditions.
- Comparable companies in the biotech space, such as Amgen, Gilead Sciences, and Regeneron, also utilize stock options as part of their executive compensation packages.
- The exercise price adjustments in this filing are not unusual and could be related to the company's stock performance or other factors.
Stakeholder Impact
- The changes in stock option prices may have a minor impact on the potential dilution of existing shareholders.
- The changes in stock option prices may impact the value of the options held by the director.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | 1/3rd of some stock options vested on this date. |
| 05/25/2024 | Date of exercisability for some of the options. |
| 12/16/2024 | Date of the stock option exercise price amendments. |
| 12/17/2024 | Date the form was signed. |
| 01/02/2032 | Date of exercisability for some of the options. |
| 05/24/2033 | Expiration date for some of the options. |
Keywords
stock options, exercise price, Rani Therapeutics, director, Lisa Ann Rometty, vesting, amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.